Danish pharmaceutical company specializing in allergy immunotherapy tablets and injections.
Danish pharmaceutical company specializing in allergy immunotherapy tablets and injections.
Patients take the tablets or injections for several years, so revenue builds from a base of ongoing treatments and reflects reimbursement rules in each country. Europe is the core, with the US a smaller but growing market. The Lundbeck Foundation, a Danish charitable holding, is the main shareholder.
Moat: narrow (IP / patents, regulatory licence, process know-how). One of few global specialists in allergy immunotherapy with approvals across many markets.
Headquarters: Horsholm, Denmark · Founded: 1923 · Employees: 2,721
Size ALK-abello A/S (ALK-B.CO) is a Denmark Health Care company (Pharmaceuticals: Major) with a market value of $7.94B, the 17th largest of 60 Denmark companies the cockpit tracks. Shares closed at DKK 243.00 on 18 Nov 2026.
Performance Over six months the shares fell 7.6%, against +9.6% for the median peer and +6.3% for the Denmark market (cap-weighted) — 7th lowest of 21 in its peer set.
Growth Revenue grew 16.2% over the last twelve months (peer median +12.8%); the operating margin is 26.5% (peer median 13.8%).
Valuation It trades at 34.8× forward earnings against a peer median of 19.2× (5th most expensive of 14).
Price implies For today's price to make sense, revenue must grow about 7% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is -5 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 19.3 points above its cost of capital (6.1% WACC).
Next results Next results expected around 9 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | DKK 7.06B | DKK 6.31B | DKK 5.54B | DKK 4.82B | DKK 4.51B |
| Revenue growth | — | +14% | +15% | +7% | — |
| Gross profit | DKK 4.80B | DKK 4.16B | DKK 3.47B | DKK 2.95B | DKK 2.72B |
| EBITDA | DKK 2.22B | DKK 1.98B | DKK 1.36B | DKK 909M | DKK 707M |
| Net income | DKK 1.40B | DKK 1.20B | DKK 815M | DKK 486M | DKK 335M |
| Free cash flow | DKK 1.91B | DKK 1.54B | DKK 953M | DKK 357M | DKK 118M |
| Capital expenditure | DKK 351M | DKK 360M | DKK 1.30B | DKK 379M | DKK 353M |
| Total debt | DKK 478M | DKK 418M | DKK 1.19B | DKK 765M | DKK 696M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| ALK-abello A/S ALK-B.CO | $7.94B | -8% | +16% | 26% | 34.8× | 7.3% |
| Allergy Therapeutics AGY.L | n/a | -84% | n/a | n/a | n/a | n/a |
| Merck & MRK | $340B | +23% | +5% | 18% | 16.4× | 8.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ALK-B.CO | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +2.2% | +1.7% | 11th highest of 21 |
| 6-month return | -7.6% | +9.6% | 7th lowest of 21 |
| Distance from 52-week high | -10.5% | -13.5% | 10th highest of 21 |
| Revenue growth (TTM) | +16.2% | +12.8% | 10th highest of 21 |
| Operating margin | 26.5% | 13.8% | 2nd highest of 20 |
| Forward P/E | 34.8× | 19.2× | 5th most expensive of 14 |
| Growth the price implies (Req g, 7 yrs) | 7.3% | 13.8% | 6th least demanding of 13 |
| Growth delivered (Del g) | +12.6% | +9.0% | 3rd highest of 13 |
| Hurdle (Req g minus delivered) | -5.3 pp | +3.7 pp | 6th least demanding of 13 |
| ROIC minus cost of capital | +19.3 pp | +1.6 pp | 3rd highest of 18 |
| EV / EBITDA | 23.7× | 18.9× | 5th most expensive of 13 |
| Net debt / EBITDA | -0.7× | 0.3× | 6th least indebted of 13 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| ALK-abello A/S ALK-B.CO | Denmark | $7.94B | -8% | +16% | 26% | 34.8× | 7.3% | +12.6% |
| Glenmark Pharmaceuticals GLENMARK.NS | India | $7.98B | +10% | 0% | 17% | 33.1× | 27.3% | +9.4% |
| Alkermes Public ALKS | United States | $7.87B | +27% | +15% | 5% | n/a | 32.5% | +7.3% |
| Shanghai Fosun Pharmaceutical (Group) 2196.HK | Hong Kong | $7.74B | -15% | +10% | 6% | 9.0× | 19.9% | +5.8% |
| Shanghai Pharmaceuticals 601607.SS | China | $8.23B | 0% | +4% | 3% | 11.2× | -10.1% | +8.1% |
| Rhythm Pharmaceuticals RYTM | United States | $8.25B | +31% | +61% | -67% | n/a | n/a | n/a |
| Amneal Pharmaceuticals AMRX | United States | $7.62B | +79% | +9% | 16% | 19.2× | 17.2% | +8.7% |
| Protagonist Therapeutics PTGX | United States | $8.30B | +26% | +164% | 59% | 1,532.5× | 17.5% | +10.0% |
| Kyowa Kirin 4151.T | Japan | $8.43B | +9% | +10% | 24% | 16.4× | -4.7% | +9.3% |
| Grifols GRF.MC | Spain | $7.48B | +19% | +1% | 16% | 13.1× | 7.1% | +7.1% |
| Kiniksa Pharmaceuticals International KNSA | United States | $7.47B | +75% | +58% | 14% | 56.6× | 10.4% | +45.5% |
| Corcept Therapeutics CORT | United States | $7.42B | +15% | +30% | 12% | 15.3× | 23.9% | +16.6% |
| Praxis Precision Medicines PRAX | United States | $8.53B | -9% | -100% | n/a | n/a | n/a | n/a |
| ONO Pharmaceutical 4528.T | Japan | $7.33B | -2% | -2% | 22% | 15.3× | -6.8% | +10.8% |
| Asymchem Laboratories (Tianjin) 002821.SZ | China | $7.27B | +20% | +18% | 17% | 37.4× | n/a | n/a |
| Cytokinetics CYTK | United States | $7.15B | -35% | +30% | -625% | n/a | n/a | n/a |
| ImmunityBio IBRX | United States | $7.13B | -17% | +121% | -150% | n/a | n/a | n/a |
| Bachem BANB.SW | Switzerland | $7.06B | 0% | +5% | 19% | 32.4× | n/a | n/a |
| Akeso 9926.HK | Hong Kong | $7.01B | -48% | +42% | -25% | n/a | n/a | n/a |
| H. Lundbeck A/S HLUN-A.CO | Denmark | $9.16B | +69% | +9% | 26% | n/a | -6.6% | +6.6% |
| Madrigal Pharmaceuticals MDGL | United States | $9.25B | -22% | +93% | -11% | 81.5× | n/a | n/a |